1766-1767 / 2605
“Lessons learned” from MGH/MDACC Phase III NSCLC trial
➢
peer review of contours is critical;
➢
image guidance with daily kV imaging and weekly CT scans is very important;
➢
modifications to treatment plans to adapt to changes in tumor or anatomy were
needed in
20% of IMRT cases and 55% of proton cases*
➢
~ 70% of all patients could be randomized, and among the randomized patients,
75% were at 74 Gy (RBE) and 25% at 66 Gy (RBE) dose levels;
➢
the rate of treatment interruption or incompletion has been extremely low.
*Note: personal experience only about 10%